OTCPK:MAHL.Y

Stock Analysis Report

Executive Summary

MediPal Holdings Corporation engages in the wholesale of prescription and OTC pharmaceuticals, cosmetics, daily necessities, animal health products, food processing raw materials, food additives, medical equipment and supplies, clinical diagnostics, etc.

Snowflake

Fundamentals

Excellent balance sheet and good value.

Share Price & News

How has MediPal Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.0%

MAHL.Y

4.6%

US Healthcare

2.3%

US Market


1 Year Return

n/a

MAHL.Y

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: Insufficient data to determine how MAHL.Y performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how MAHL.Y performed against the US Market.


Shareholder returns

MAHL.YIndustryMarket
7 Day2.0%4.6%2.3%
30 Day3.4%-0.1%-1.0%
90 Day3.6%-4.5%-0.7%
1 Yearn/a-7.1%-8.5%7.9%5.6%
3 Year34.3%34.3%31.9%26.5%45.6%36.3%
5 Year96.8%96.8%63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is MediPal Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is MediPal Holdings undervalued compared to its fair value and its price relative to the market?

15.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: MAHL.Y ($22.49) is trading below our estimate of fair value ($26.75)

Significantly Undervalued: MAHL.Y is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MAHL.Y is good value based on its PE Ratio (16x) compared to the Healthcare industry average (20.3x).

PE vs Market: MAHL.Y is good value based on its PE Ratio (16x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: MAHL.Y is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: MAHL.Y is good value based on its PB Ratio (1.1x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is MediPal Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

5.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MAHL.Y's forecast earnings growth (5% per year) is above the savings rate (2.7%).

Earnings vs Market: MAHL.Y's earnings (5% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: MAHL.Y's earnings are forecast to grow, but not significantly.

Revenue vs Market: MAHL.Y's revenue (1.7% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: MAHL.Y's revenue (1.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: MAHL.Y's Return on Equity is forecast to be low in 3 years time (7%).


Next Steps

Past Performance

How has MediPal Holdings performed over the past 5 years?

9.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MAHL.Y's earnings have grown by 9.2% per year over the past 5 years.

Accelerating Growth: MAHL.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MAHL.Y had negative earnings growth (-8.2%) over the past year, making it difficult to compare to the Healthcare industry average (5.3%).


Return on Equity

High ROE: MAHL.Y's Return on Equity (7.4%) is considered low.


Return on Assets

ROA vs Industry: MAHL.Y's Return on Assets is below or equal to the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: MAHL.Y's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is MediPal Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MAHL.Y's short term assets (¥1,164.2B) exceeds its short term liabilities (¥959.4B)

Long Term Liabilities: MAHL.Y's short term assets (1,164.2B) exceeds its long term liabilities (88.0B)


Debt to Equity History and Analysis

Debt Level: MAHL.Y's debt to equity ratio (9.5%) is considered satisfactory

Reducing Debt: MAHL.Y's debt to equity ratio has increased from 8.6% to 9.5% over the past 5 years.

Debt Coverage: MAHL.Y's debt is well covered by operating cash flow (113.6%).

Interest Coverage: MAHL.Y earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: MAHL.Y has a high level of physical assets or inventory.

Debt Coverage by Assets: MAHL.Y's debt is covered by short term assets (assets are 20.757290x debt).


Next Steps

Dividend

What is MediPal Holdings's current dividend yield, its reliability and sustainability?

1.63%

Current Dividend Yield


Dividend Yield vs Market

company1.6%marketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Years1.6%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: MAHL.Y's dividend (1.63%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: MAHL.Y's dividend (1.63%) is low compared to the top 25% of dividend payers in the US market (3.76%).

Stable Dividend: MAHL.Y's dividend payments have been volatile in the past 10 years.

Growing Dividend: MAHL.Y's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (24.8%), MAHL.Y's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of MediPal Holdings's salary, the management and board of directors tenure and is there insider trading?

7.1yrs

Average management tenure


CEO

Shuichi Watanabe (67yo)

7.5yrs

Tenure

0

Mr. Shuichi Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since April 2012. Mr. Watanabe served as the Chief Executive Officer and President of Mediceo Corporation ...


Management Age and Tenure

7.1yrs

Average Tenure

Experienced Management: MAHL.Y's management team is seasoned and experienced (7.1 years average tenure).


Board Age and Tenure

7.3yrs

Average Tenure

65yo

Average Age

Experienced Board: MAHL.Y's board of directors are considered experienced (7.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Shuichi Watanabe (67yo)

    CEO, President & Representative Director

    • Tenure: 7.5yrs
  • Toshihide Yoda (56yo)

    Senior MD

    • Tenure: 9.8yrs
  • Hideaki Takemura

    Managing Executive Officer & Deputy GM of Business Development Department

    • Tenure: 0yrs
  • Yasuhiro Choufuku

    Senior MD & Director

    • Tenure: 12.8yrs
  • Masanori Kawahara

    Managing Executive Officer

    • Tenure: 0yrs
  • Masaaki Shimizu

    Managing Executive Officer & Manager of Secretarial Office - Administration Division

    • Tenure: 0yrs
  • Kenichi Takase

    Executive Officer & Manager of Corporate Planning Department - Administration Division

    • Tenure: 0yrs
  • Yuji Sakon

    MD, GM of Administration Division & Director

    • Tenure: 7.8yrs
  • Shinjiro Watanabe

    GM of Information Systems Mgmt. Div

    • Tenure: 6.8yrs
  • Kimio Nakamura

    Executive Officer & Deputy GM of Administration Division

    • Tenure: 0yrs

Board Members

  • Shuichi Watanabe (67yo)

    CEO, President & Representative Director

    • Tenure: 7.5yrs
  • Toshihide Yoda (56yo)

    Senior MD

    • Tenure: 9.8yrs
  • Takuro Hasegawa

    Director

    • Tenure: 15.8yrs
  • Yasuhiro Choufuku

    Senior MD & Director

    • Tenure: 12.8yrs
  • Kuniko Shoji

    Outside Director

    • Tenure: 1.8yrs
  • Toshio Asano (67yo)

    Outside Director

    • Tenure: 2.8yrs
  • Kunio Ninomiya (63yo)

    Director

    • Tenure: 3.3yrs
  • Yuji Sakon

    MD, GM of Administration Division & Director

    • Tenure: 7.8yrs
  • Shinjiro Watanabe

    GM of Information Systems Mgmt. Div

    • Tenure: 6.8yrs
  • Mitsuko Kagami

    Outside Director

    • Tenure: 5.8yrs

Company Information

MediPal Holdings Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MediPal Holdings Corporation
  • Ticker: MAHL.Y
  • Exchange: OTCPK
  • Founded: 1898
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: JP¥544.594b
  • Listing Market Cap: JP¥5.009b
  • Shares outstanding: 222.46m
  • Website: https://www.medipal.co.jp

Number of Employees


Location

  • MediPal Holdings Corporation
  • 2-7-15, Yaesu
  • Chuo-ku
  • Tokyo
  • 104-8461
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7459TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYSep 1995
MEPD.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 1995
MAHL.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDNov 2008

Biography

MediPal Holdings Corporation engages in the wholesale of prescription and OTC pharmaceuticals, cosmetics, daily necessities, animal health products, food processing raw materials, food additives, medical e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:06
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.